DAN JACOBS: Open Payments
NPI 1831213263 · FORT WASHINGTON, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,911 in 175 payments from 13 companies in 2025. Trend: 2023 $1,469 · 2024 $1,710 · 2025 $1,911
Food & beverage: $1,911
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 54 | $331 |
| Otsuka America Pharmaceutical, Inc. | 25 | $307 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 35 | $261 |
| Neurocrine BioSciences, Inc. | 17 | $239 |
| Vanda Pharmaceuticals Inc. | 13 | $236 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $149 |
| Alkermes, Inc. | 6 | $127 |
| Lundbeck LLC | 6 | $94 |
| E.R. Squibb & Sons, L.L.C. | 2 | $47 |
| Axsome Therapeutics, Inc. | 2 | $42 |
Products named: REXULTI, VRAYLAR, CAPLYTA, INGREZZA, FANAPT, TRINTELLIX, ARISTADA, COBENFY.
Industry payments across PA — which companies pay providers there.
